Literature DB >> 12773325

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.

Harold R Collard1, Talmadge E King, Becki Bucher Bartelson, Jason S Vourlekis, Marvin I Schwarz, Kevin K Brown.   

Abstract

There is significant heterogeneity in survival time among patients with idiopathic pulmonary fibrosis. Studies of baseline clinical and physiologic variables as predictors of survival time have reported inconsistent results. We evaluated the predictive value of changes in clinical and physiologic variables over time for survival time in 81 patients with biopsy-proven idiopathic pulmonary fibrosis. Six-month changes in dyspnea score, total lung capacity, thoracic gas volume, FVC, FEV1, diffusing capacity of carbon monoxide, partial pressure of arterial oxygen, oxygen saturation, and alveolar-arterial oxygen gradient were predictive of survival time even after adjustment for baseline values. Analyses were repeated on 51 patients with 12-month change data. Twelve-month changes in dyspnea score, total lung capacity, FVC, partial pressure of arterial oxygen, oxygen saturation, and alveolar-arterial oxygen gradient were predictive of survival time after adjustment for baseline values. Evaluation of changes in clinical and physiological variables over 6 and 12 months may provide clinicians with more accurate prognostic information than baseline values alone.

Entities:  

Mesh:

Year:  2003        PMID: 12773325     DOI: 10.1164/rccm.200211-1311OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  180 in total

1.  Modulation of lung inflammation by the Epstein-Barr virus protein Zta.

Authors:  James F Guenther; Jennifer E Cameron; Hong T Nguyen; Yu Wang; Deborah E Sullivan; Bin Shan; Joseph A Lasky; Erik K Flemington; Gilbert F Morris
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

2.  Pneumothorax and idiopathic pulmonary fibrosis.

Authors:  Tae Iwasawa; Takashi Ogura; Hiroshi Takahashi; Akira Asakura; Toshiyuki Gotoh; Takuya Yazawa; Tomio Inoue
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

3.  Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Akiko Sano; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Chron Respir Dis       Date:  2015-09-15       Impact factor: 2.444

4.  Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis.

Authors:  D J Lederer; S M Arcasoy; R G Barr; J S Wilt; E Bagiella; F D'Ovidio; J R Sonett; S M Kawut
Journal:  Am J Transplant       Date:  2006-07-26       Impact factor: 8.086

5.  Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis.

Authors:  Xueren Li; Shouchun Peng; Luqing Wei; Zhenhua Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

6.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

7.  Linking parenchymal disease progression to changes in lung mechanical function by percolation.

Authors:  Jason H T Bates; Gerald S Davis; Arnab Majumdar; Kelly J Butnor; Béla Suki
Journal:  Am J Respir Crit Care Med       Date:  2007-06-15       Impact factor: 21.405

8.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

9.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

10.  Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Authors:  Sean J Callahan; Meng Xia; Susan Murray; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-08-31       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.